Atea Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Atea Pharmaceuticals generated cash of -$85,395,000, which is more than the previous year. Cash used in financing activities reached the amount of $257,000 last year. Net change in cash is therefore -$44,835,000.
Cash Flow
| 2018 | -7.90M | -12K | 27.48M |
|---|---|---|---|
| 2019 | -12.81M | -2K | -15K |
| 2020 | 296.73M | -26K | 531.74M |
| 2021 | -87.00M | -4K | 1.46M |
| 2022 | -120.98M | -455.41M | 370K |
| 2023 | -85.39M | 40.30M | 257K |
AVIR Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 188.65M | 764.68M | 850.22M | 21.76M | 34.59M | 15.03M |
Operating activities | ||||||
Net income | -135.95M | -115.90M | 121.19M | -10.94M | -14.03M | -9.06M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 416K | 260K | 29K | 19K | 17K | 17K |
Stock-based compensation expense | 49.42M | 46.71M | 39.62M | 7.45M | 624K | 0 |
| Deferred income tax benefit | 49.42M | 46.71M | 39.62M | 7.45M | 624K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | -5.81M | 0 | 0 |
Inventories | 0 | 0 | 0 | 5.14M | 0 | 0 |
Accounts payable | 1.70M | -1.98M | 10.28M | -488K | 157K | -90K |
Cash generated by operating activities | -85.39M | -120.98M | -87.00M | 296.73M | -12.81M | -7.90M |
Investing activities | ||||||
Purchases Of Investments | -562.36M | -545.35M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -1.94M | -4K | -26K | -2K | -12K |
Acquisitions Net | 0 | 453.46K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 40.30M | -455.41M | -4K | -26K | -2K | -12K |
Financing activities | ||||||
Common Stock Issued | 257K | 230K | 1.46M | 317.63M | -15K | 124K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 257K | 370K | 1.46M | 531.74M | -15K | 27.48M |
Net Change In Cash | -44.83M | -576.02M | -85.54M | 828.45M | -12.83M | 19.56M |
Cash at end of period | 143.82M | 188.65M | 764.68M | 850.22M | 21.76M | 34.59M |
| Data source | Data source | Data source |